Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 258Lung Neoplasms 207Adenocarcinoma of Lung 44Small Cell Lung Carcinoma 31Adenocarcinoma, Bronchiolo-Alveolar 23Brain Neoplasms 17Breast Neoplasms 14Neoplasm Metastasis 12Mesothelioma, Malignant 10Radiation Injuries 8Neoplasms 8Prostatic Neoplasms 7Melanoma 7Thymoma 6Squamous Cell Carcinoma of Head and Neck 6NSCLC 6Head and Neck Neoplasms 6Drug-Related Side Effects and Adverse Reactions 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 4Esophageal Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Kidney Neoplasms 3Esthesioneuroblastoma, Olfactory 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Thyroid Neoplasms 2

Interventions

Radiotherapy 4Immune Checkpoint Inhibitors 4famitinib 1camrelizumab 1aflutinib 1Oxaliplatin 1Nivolumab 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced NSCLC × Radiotherapy × Thoracic × Clear all
NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡